Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Blocklisting Six Monthly Return

29 Jun 2015 07:00

RNS Number : 4650R
Hutchison China Meditech Limited
29 June 2015
 

 

 

 

Blocklisting Six Monthly Return

 

 

London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 

Hutchison China MediTech Limited

2.

Name of scheme:

 

Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:

 

From 29 December 2014 to 28 June 2015

4.

Balance under scheme from previous return:

 

696,051 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 

Nil

6.

Number of securities issued/allotted under scheme during period:

223,288 ordinary shares of US$1 each

7.

Balance under scheme not yet issued/allotted at end of the period:

 

472,763 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 

2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:

53,299,964 ordinary shares of US$1 each

Name of contact:

 

Christian Hogg

Address of contact:

 

21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 

+852 2121 8200

 

 

Ends

 

 

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

 

Panmure Gordon (UK) Limited

Telephone: +44 20 7886 2500

Richard Gray

Andrew Potts

 

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

 

About Chi-Med

 

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:1). For more information, please visit: www.chi-med.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRUKSVRVWANURR
Date   Source Headline
29th Jun 20229:30 amRNSBlocklisting Six Monthly Return
27th Jun 20229:30 amRNSHUTCHMED to Announce 2022 Half-Year Results
1st Jun 20229:30 amRNSTAZVERIK® Approved in Hainan Pilot Zone
24th May 202211:00 amRNSLTIP and Share Options
16th May 202212:00 pmRNSAppointment of Non–Executive Director
3rd May 20227:00 amRNSHUTCHMED Receives CRL from the US FDA
27th Apr 20222:30 pmRNSAnnual General Meeting Poll Results
21st Apr 20229:30 amRNSVesting of awards under Long Term Incentive Plan
31st Mar 20227:00 amRNSUpdate on Status under HFCAA
23rd Mar 20228:30 amRNS2021 Annual Report and Notice of AGM
11th Mar 20229:00 amRNSUpdate on Status under HFCAA
9th Mar 20228:30 amRNSVesting of awards under Long Term Incentive Plan
7th Mar 20227:00 amRNSHUTCHMED Receives $15m Milestone from AstraZeneca
3rd Mar 20223:30 pmRNSPublication of Form 20-F
3rd Mar 202212:30 pmRNSRetirement of CEO and appointment of new CEO
3rd Mar 202212:00 pmRNSFull Year Results and Business Updates
1st Mar 20228:30 amRNSApproval to Commercialize ELUNATE® in Macau
7th Feb 20228:30 amRNSHUTCHMED to Announce 2021 Final Results
4th Feb 20229:30 amRNSPhase Ib/II Combination Study of HMPL-453
20th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Trial of HMPL-653
19th Jan 20227:00 amRNSHUTCHMED Data at ASCO GI Cancers Symposium
17th Jan 20229:00 amRNSHolding(s) in Company
12th Jan 202211:00 amRNSBreakthrough Therapy Designation for HMPL-523
10th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Study of HMPL-760
31st Dec 20217:00 amRNSBlocklisting Six Monthly Return
31st Dec 20217:00 amRNSTotal Voting Rights
20th Dec 20217:00 amRNSHUTCHMED Included in FTSE Russell Indexes
15th Dec 20219:45 amRNSGrant of Share Options and Awards under LTIP
14th Dec 20217:00 amRNSHMPL-523 Clinical Data Presented at ASH
10th Dec 202110:00 amRNSHUTCHMED Presents Data at ESMO Immuno-Oncology ‘21
6th Dec 20217:00 amRNSHUTCHMED Completes Planned Enrollment of FRESCO-2
3rd Dec 20217:00 amRNSUpdated NRDL to include ELUNATE and SULANDA
30th Nov 20218:30 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSHUTCHMED and AZ Initiate SACHI Phase 3 Trial
8th Nov 20217:00 amRNSHUTCHMED to Present Clinical Data at ASH
1st Nov 20217:00 amRNSHUTCHMED and AZ Initiate SAMETA Global P3 Trial
29th Oct 20219:30 amRNSTotal Voting Rights
28th Oct 20217:00 amRNSHUTCHMED Initiates Phase III Trial of HMPL-523
20th Oct 20219:30 amRNSGrant of Awards under Long Term Incentive Plan
30th Sep 20219:30 amRNSTotal Voting Rights
29th Sep 20217:00 amRNSClosure of Non-Core OTC Joint Venture Divestment
29th Sep 20217:00 amRNSHUTCHMED Highlights Presentations at CSCO 2021
21st Sep 20217:00 amRNSHUTCHMED Initiates Phase III Trial SURTORI-01
20th Sep 20217:00 amRNSJapan Bridging Study For Surufatinib Initiated
13th Sep 20217:00 amRNSBreakthrough Therapy Designation for Amdizalisib
8th Sep 202111:30 amRNSHUTCHMED and AZ Initiate Phase III Trial in China
7th Sep 20219:30 amRNSHUTCHMED to Present Clinical Data at ESMO
2nd Sep 202112:45 pmRNSGrant of Share Options, and Awards under LTIP
31st Aug 20219:30 amRNSTotal Voting Rights
26th Aug 20217:00 amRNSPhase Ib/II Trial of Fruquintinib & Tislelizumab

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.